OptimizeRx Corporation filed a Form 8-K on November 13, 2026, reporting that it issued a press release on November 11, 2026, announcing financial results for the third quarter ended September 30, 2026, along with updated 2026 revenue guidance.

Key Highlights

  • Event date: The earliest reported event is November 11, 2026, the date OptimizeRx issued its Q3 2026 earnings press release.
  • Reporting period: The financial results disclosed cover the third quarter ended September 30, 2026.
  • Updated guidance: According to the filing, the press release also included updated 2026 revenue guidance.
  • Investor call: The company hosted an investor conference call on November 11, 2026, to discuss the press release and take questions from the investment community.
  • Exhibits furnished: A press release (Exhibit 99.1) and a conference call transcript (Exhibit 99.2) are furnished with the filing, both dated November 11, 2026.
  • Signing officer: The filing was signed by Edward Stelmakh, Chief Financial and Strategy Officer, on November 13, 2026.

OptimizeRx Reports Q3 2026 Results and Revises Revenue Outlook via 8-K

OptimizeRx Corporation (NASDAQ:OPRX), incorporated in Nevada and headquartered at 260 Charles Street, Suite 302, Waltham, MA 02453, filed a current report under Item 2.02 (Results of Operations and Financial Condition) disclosing that it publicly released third-quarter financial results for the period ended September 30, 2026. The press release, dated November 11, 2026, also contained updated 2026 revenue guidance, according to the filing.

In addition to the press release, the company disclosed that it held an investor conference call on November 11, 2026, to discuss the contents of the press release and to give the investment community an opportunity to ask questions. A transcript of that call is furnished as Exhibit 99.2. The filing notes that the information in Item 2.02, including both exhibits, is furnished and "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," meaning it is not subject to the liabilities of that section.

The 8-K was signed on November 13, 2026, by Edward Stelmakh in his capacity as Chief Financial and Strategy Officer. The company's common stock, with a par value of $0.001, is registered on the Nasdaq Capital Market under the trading symbol OPRX. The filing does not include the underlying financial figures from the press release or conference call transcript within the body of the 8-K itself; those details are contained in the furnished exhibits.

What Was Disclosed

OptimizeRx filed this 8-K to announce the furnishing of its Q3 2026 earnings press release and investor call transcript, both dated November 11, 2026, covering results for the quarter ended September 30, 2026, and updated 2026 revenue guidance.